Click for best price
Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Share 2022
This report contains market size and forecasts of Resistant Pseudomonas Aeruginosa Infections Drugs in global, including the following market information:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Resistant Pseudomonas Aeruginosa Infections Drugs companies in 2021 (%)
The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Semi-Synthetic Penicillin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma and Shionogi & Co Ltd. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Type, 2021 (%)
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Home Care
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues share in global market, 2021 (%)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd
| Report Attributes |
Report Details |
| Report Title |
Resistant Pseudomonas Aeruginosa Infections Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
74 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Overall Market Size
2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size: 2021 VS 2028
2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.2 Top Global Resistant Pseudomonas Aeruginosa Infections Drugs Companies Ranked by Revenue
3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Companies
3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Companies
3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Resistant Pseudomonas Aeruginosa Infections Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.8.1 List of Global Tier 1 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Markets, 2021 & 2028
4.1.2 Semi-Synthetic Penicillin
4.1.3 Cephalosporin
4.1.4 Lactam Drugs
4.1.5 Others
4.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
4.2.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
4.2.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
4.2.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
4.3.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
4.3.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
4.3.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Home Care
5.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
5.2.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
5.2.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
5.2.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
5.3.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
5.3.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
5.3.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2021 & 2028
6.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
6.2.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
6.2.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
6.2.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
6.3.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
6.3.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
6.3.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.4.2 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.4.3 US Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.4.4 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.4.5 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.5.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.5 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.6 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.7 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.9 Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.6.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.4 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.5 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.7 India Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.7.2 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.7.3 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.7.4 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.8.3 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.4 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.6 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 ContraFect Corp
7.1.1 ContraFect Corp Corporate Summary
7.1.2 ContraFect Corp Business Overview
7.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.1.5 ContraFect Corp Key News
7.2 Inhibrx LP
7.2.1 Inhibrx LP Corporate Summary
7.2.2 Inhibrx LP Business Overview
7.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Inhibrx LP Key News
7.3 Achaogen Inc
7.3.1 Achaogen Inc Corporate Summary
7.3.2 Achaogen Inc Business Overview
7.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Achaogen Inc Key News
7.4 LegoChem Biosciences Inc
7.4.1 LegoChem Biosciences Inc Corporate Summary
7.4.2 LegoChem Biosciences Inc Business Overview
7.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.4.5 LegoChem Biosciences Inc Key News
7.5 Melinta Therapeutics Inc
7.5.1 Melinta Therapeutics Inc Corporate Summary
7.5.2 Melinta Therapeutics Inc Business Overview
7.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Melinta Therapeutics Inc Key News
7.6 Novartis AG
7.6.1 Novartis AG Corporate Summary
7.6.2 Novartis AG Business Overview
7.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Novartis AG Key News
7.7 AmpliPhi Biosciences Corp
7.7.1 AmpliPhi Biosciences Corp Corporate Summary
7.7.2 AmpliPhi Biosciences Corp Business Overview
7.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.7.5 AmpliPhi Biosciences Corp Key News
7.8 Biolytics Pharma
7.8.1 Biolytics Pharma Corporate Summary
7.8.2 Biolytics Pharma Business Overview
7.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Biolytics Pharma Key News
7.9 Shionogi & Co Ltd
7.9.1 Shionogi & Co Ltd Corporate Summary
7.9.2 Shionogi & Co Ltd Business Overview
7.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Shionogi & Co Ltd Key News
8 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, Analysis
8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, 2017-2028
8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Resistant Pseudomonas Aeruginosa Infections Drugs Supply Chain Analysis
10.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Value Chain
10.2 Resistant Pseudomonas Aeruginosa Infections Drugs Upstream Market
10.3 Resistant Pseudomonas Aeruginosa Infections Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Resistant Pseudomonas Aeruginosa Infections Drugs in Global Market
Table 2. Top Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
Table 9. List of Global Tier 1 Resistant Pseudomonas Aeruginosa Infections Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2017-2022
Table 15. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2017-2022
Table 20. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2017-2022
Table 25. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2023-2028
Table 26. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2023-2028
Table 46. ContraFect Corp Corporate Summary
Table 47. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 48. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Inhibrx LP Corporate Summary
Table 50. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 51. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Achaogen Inc Corporate Summary
Table 53. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 54. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. LegoChem Biosciences Inc Corporate Summary
Table 56. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 57. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Melinta Therapeutics Inc Corporate Summary
Table 59. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 60. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Novartis AG Corporate Summary
Table 62. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 63. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. AmpliPhi Biosciences Corp Corporate Summary
Table 65. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 66. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Biolytics Pharma Corporate Summary
Table 68. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 69. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Shionogi & Co Ltd Corporate Summary
Table 71. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 72. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 74. Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 75. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region, 2017-2022 (K Pcs)
Table 76. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region, 2023-2028 (K Pcs)
Table 77. Resistant Pseudomonas Aeruginosa Infections Drugs Market Opportunities & Trends in Global Market
Table 78. Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers in Global Market
Table 79. Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints in Global Market
Table 80. Resistant Pseudomonas Aeruginosa Infections Drugs Raw Materials
Table 81. Resistant Pseudomonas Aeruginosa Infections Drugs Raw Materials Suppliers in Global Market
Table 82. Typical Resistant Pseudomonas Aeruginosa Infections Drugs Downstream
Table 83. Resistant Pseudomonas Aeruginosa Infections Drugs Downstream Clients in Global Market
Table 84. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type
Figure 2. Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application
Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2021
Figure 9. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 19. US Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 24. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 33. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Resistant Pseudomonas Aeruginosa Infections Drugs by Region, 2021 VS 2028
Figure 50. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Value Chain
Figure 51. Marketing Channels
